The cognitive effects of esketamine: what do we know so far?
Introduction Esketamine is an S-enantiomer of ketamine approved by the EMA for treatment-resistant depression (TRD). As an NMDA receptor antagonist, its administration results in increase of glutamate release and AMPA receptor activation, supporting both rapid-onset and long-term antidepressant eff...
| Auteurs principaux: | , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Cambridge University Press
2022-06-01
|
| Collection: | European Psychiatry |
| Sujets: | |
| Accès en ligne: | https://www.cambridge.org/core/product/identifier/S092493382201879X/type/journal_article |